Anti-androgens in the treatment of prostate cancer and risk of secondary cancers: Overview of non clinical models and regulatory perspectives

被引：0

|

作者：

Belhouari, H. ^{[1
]}

Vidil, F. ^{[1
]}

Louin, G. ^{[1
]}

Burbank, M. ^{[1
]}

Richard, A. ^{[1
]}

Salomon, V. ^{[1
]}

机构：

[1] ANSM, DMS, St Denis, France

来源：

TOXICOLOGY LETTERS | 2021年 / 350卷

关键词：

D O I：

暂无

中图分类号：

R99 [毒物学（毒理学）];

学科分类号：

100405 ;

摘要：

P13-20

引用

收藏

页码：S156 / S157

页数：2

相关论文

共 22 条

[21] Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: A secondary analysis of the NRG oncology RTOG 0415 randomized clinical trial.
Carpenter, David James
Salama, Joseph Kamel
Lee, W. Robert
Boyer, Matthew J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[22] The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials
Chen, Shubin
Mo, Wanying
Jiang, Wei
Zhou, Shaozhang
Gan, Haijie
Yu, Qitao
FRONTIERS IN IMMUNOLOGY, 2023, 14